A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2124 participants.

Also called NCT01830543

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 2,124 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01830543
  • EudraCT 2012-001491-11
Other papers using this trial's data
  • Association of International Normalized Ratio Stability and Bleeding Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention Circulation. Cardiovascular interventions, 2019-02 DOI, PubMed 30704287
  • Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial JACC. Cardiovascular interventions, 2018-04-09 DOI, PubMed 29550085
  • Novel Oral Anticoagulant Based Versus Vitamin K Antagonist Based Double Therapy Among Stented Patients With Atrial Fibrillation: Insights From the PIONEER AF-PCI Trial Circulation. Cardiovascular interventions, 2019-11 DOI, PubMed 31707805
  • Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI The New England journal of medicine, 2016-12-22 DOI, PubMed 27959713
  • Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy Circulation, 2017-01-24 DOI, PubMed 27881555, PMC5266420 PubMed links an erratum for this paper. Erratum: PMID 28320814 In the PMC Open Access subset under CC BY.
  • Total bleeding with rivaroxaban versus warfarin in patients with atrial fibrillation receiving antiplatelet therapy after percutaneous coronary intervention Journal of thrombosis and thrombolysis, 2018-10 DOI, PubMed 29943350

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Chile, Czechia, Denmark, France, Germany, Malaysia, Mexico, Netherlands, Poland, Romania, Russia, South Africa, South Korea, Sweden, Taiwan, Türkiye, Ukraine, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01830543. Randomized; no masking; primary purpose treatment. Start 2013-05-10 (actual); primary completion 2016-07-28 (actual). Results posted on 2017-07-31.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention
Acronym
PIONEER AF-PCI
Intervention (Drug)
rivaroxaban 2.5 mg
Intervention (Drug)
rivaroxaban 15 mg
Intervention (Drug)
rivaroxaban 10 mg
Intervention (Drug)
aspirin (ASA)
Intervention (Drug)
vitamin K antagonist (VKA)
Intervention (Drug)
clopidogrel
Intervention (Drug)
prasugrel
Intervention (Drug)
ticagrelor
Lead sponsor
Janssen Scientific Affairs, LLC (class: industry)
Collaborator
Bayer (class: industry)

Record details

Record id
cardio:ct-nct01830543
Content hash
42f17ac0bfde9ddd8359bdd53fc6ee813eadb0120bfadfa2fc95db9fde2bc4a1